National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES.

1956. No. 75.

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1956.*

I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1956.

Dated this  thirty first

day of  October , 1956.

W. J. Slim

Governor-General.

By His Excellency’s Command,

(Sgd.) Donald A. Cameron

Minister of State for Health.

Amendments of the National Health (Pharmaceutical Benefits) Regulations. 

Commencement.

1. These Regulations shall come into operation on the first day of November, 1956.

Writing of prescriptions.

2. Regulation 17 of the National Health (Pharmaceutical Benefits) Regulations is amended—

(a)by inserting in sub-regulation (4.), after the words “Cortisone Acetate” (first occurring), the words “, Hydrocortisone, Prednisolone or Prednisone”; and

(b) by omitting from paragraph (b)of sub-regulation (4.) the words “Cortisone Acetate” and inserting in their stead the words “that general pharmaceutical benefit”.

Supply of pharmaceutical benefits on prescriptions.

3. Regulation 20 of the National Health (Pharmaceutical Benefits) Regulations is amended by inserting in sub-regulation (2.), after the words “Cortisone Acetate”, the words “, Hydrocortisone, Prednisolone or Prednisone”.

Supply of pharmaceutical benefit before surrender of written prescription.

4. Regulation 21 of the National Health (Pharmaceutical Benefits) Regulations is amended—

(a)by inserting in sub-regulation (2.), after the words “Cortisone Acetate”, the words “, Hydrocortisone, Prednisolone or Prednisone”;

(b)by inserting in sub-regulation (4.), after the words “Cortisone Acetate” (first occurring), the words “, Hydrocortisone, Prednisolone or Prednisone”; and

* Notified in the Commonwealth Gazette on , 1956.

  Statutory Rules 1956, No. 54.

5660/56.—Price 3d. 9/12.10.1956.

(c) by omitting from paragraph (b)of sub-regulation (4.) the words “Cortisone Acetate” and inserting in their stead the words “pharmaceutical benefit”.

First Schedule.

5. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting items 100, 102, 125, 155 and 160.

Second Schedule.

6. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by omitting from item 10 the words—

“Systemic lupus erythematosus or allied conditions”

and inserting in their stead the words—

“Systemic lupus erythematosus

Dermatomyositis

Pemphigus

Periarteritis nodosa

Scleroderma”;

(b) by adding at the end of item 18 the words—

“Macrocytic anaemia”;

(c) by inserting after item 18 the following item:—

“18a Hydrocortisone ..................... Any disease or purpose specified in this column in relation to Cortisone Acetate”;

(d) by inserting after item 19 the following items:—

“19a	Mercaptopurine ...................................................	The leukaemias
“19b	Mestinon ...................................................	Myasthenia gravis”;

(e) by inserting after item 20 the following item:—

“20a Myleran ..................................................... The leukaemias”;

(f) by inserting after item 27 the following items:—

“27a	Prednisolone ....................................................	Any disease or purpose specified in this column in relation to Cortisone Acetate
“27b	Prednisone ....................................................	Any disease or purpose specified in this column in relation to Cortisone Acetate”; and

(g) by inserting after item 37 the following item:—

“37a Suprarenal Cortex Extract Adrenal failure”.

Third Schedule.

7. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by omitting from the heading of Form D the words “cortisone acetate” and inserting in their stead the words “A pharmaceutical benefit referred to in regulation 17 (4.)”; and

(b)by omitting from Form D the words “for the general pharmaceutical benefit Cortisone Acetate” and inserting in their stead the words “for , being a pharmaceutical benefit referred to in that sub-regulation,”.

 

By Authority: A. J. Arthur, Commonwealth Government Printer, Canberra.